Login to Your Account



Jazz lands first patient in phase III test of Xyrem follow-on

By Michael Fitzhugh
Staff Writer

Thursday, March 16, 2017

Jazz Pharmaceuticals plc enrolled the first patient in a phase III trial of JZP-258, a follow-on to its banner drug for narcolepsy symptoms, Xyrem.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription